Phase I Trial of Upamostat Combined With Gemcitabine in Locally Unresectable or Metastatic Pancreatic Cancer: Safety and Preliminary Efficacy Assessment

Phase I Trial of Upamostat Combined With Gemcitabine in Locally Unresectable or Metastatic Pancreatic Cancer: Safety and Preliminary Efficacy Assessment

ABSTRACT Aim This study aimed to determine the maximum tolerated dose (MTD) of the urokinase plasminogen activator (uPA) inhibitor upamostat (LH011) in combination with gemcitabine for locally advanced unresectable or metastatic pancreatic cancer. Method Seventeen patients were enrolled and received...

Full description

Saved in:
Bibliographic Details
Main Authors: Xiuping Lai, Di Cheng, Huixin Xu, Jingshu Wang, Xiaozhi Lv, Herui Yao, Liuning Li, Junyan Wu, Suiwen Ye, Zhihua Li
Format: Article
Language:English
Published: Wiley 2025-01-01
Series:Cancer Medicine
Subjects:
LH011
maximum tolerated dose
pancreatic cancer
upamostat
urokinase inhibitor
Online Access:https://doi.org/10.1002/cam4.70550
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1002/cam4.70550

Similar Items